Showing 1 - 10 results of 10 for search 'Jeyakumar, D', query time: 0.05s
Refine Results
-
1
-
2
AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML)... by Daver, N, Vyas, P, Kambhampati, S, Malki, MA, Larson, R, Asch, A, Mannis, G, Chai-Ho, W, Tanaka, T, Bradley, T, Jeyakumar, D, Wang, E, Xing, G, Chao, M, Ramsingh, G, Renard, C, Lal, I, Zeidner, J, Sallman, D
Published 2022Conference item -
3
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results by Daver, NG, Vyas, P, Kambhampati, S, Al Malki, MM, Larson, RA, Asch, AS, Mannis, GN, Chai-Ho, W, Tanaka, TN, Bradley, TJ, Jeyakumar, D, Wang, ES, Xing, G, Chao, M, Ramsingh, G, Renard, C, Lal, I, Zeidner, JF, Sallman, DA
Published 2022Journal article -
4
MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results by Sallman, D, Malki, MA, Asch, A, Wang, E, Jurcic, J, Bradley, T, Flinn, I, Pollyea, D, Kambhampati, S, Tanaka, T, Zeidner, J, Garcia-Manero, G, Jeyakumar, D, Gu, L, Tan, A, Chao, M, O'Hear, C, Lal, I, Vyas, P, Daver, N
Published 2022Conference item -
5
Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes: 5F9005 phase 1b study results by Sallman, DA, Al Malki, MM, Asch, AS, Wang, ES, Jurcic, JG, Bradley, TJ, Flinn, IW, Pollyea, DA, Kambhampati, SN, Tanaka, TN, Zeidner, JF, Garcia-Manero, G, Jeyakumar, D, Gu, L, Tan, A, Chao, M, O'Hear, C, Lal, I, Vyas, P, Daver, N
Published 2022Conference item -
6
Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase ib results by Daver, NG, Vyas, P, Kambhampati, S, Al Malki, MM, Larson, RA, Asch, AS, Mannis, G, Chai-Ho, W, Tanaka, TN, Bradley, TJ, Jeyakumar, D, Wang, ES, Sweet, K, Kantarjian, HM, Garcia-Manero, G, Komrokji, R, Xing, G, Ramsingh, G, Renard, C, Zeidner, JF, Sallman, DA
Published 2023Journal article -
7
The first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results by Sallman, D, Asch, A, Kambhampati, S, Al Malki, M, Zeidner, J, Donnellan, W, Lee, D, Vyas, P, Jeyakumar, D, Mannis, G, Tanaka, T, Chai-Ho, W, Larson, R, Whiteley, A, Marcucci, G, Komrokji, R, Garcia-Manero, G, Van Elk, J, Lin, M, Maute, R, Volkmer, J-P, Takimoto, C, Chao, M, Daver, N
Published 2021Conference item -
8
Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study by Sallman, DA, Al Malki, MM, Asch, AS, Wang, ES, Jurcic, JG, Bradley, TJ, Flinn, IW, Pollyea, DA, Kambhampati, S, Tanaka, TN, Zeidner, JF, Garcia-Manero, G, Jeyakumar, D, Komrokji, R, Lancet, J, Kantarjian, HM, Gu, L, Zhang, Y, Tan, A, Chao, M, O'Hear, C, Ramsingh, G, Lal, I, Vyas, P, Daver, NG
Published 2023Journal article -
9
A phase 1B/2 study of the CD123-targeting antibody-drug conjugate pivekimab sunirine (IMGN632) in combination with venetoclax (VEN) and azacitidine (AZA) for patients with CD123-po... by Daver, NG, Montesinos, P, Aribi, A, Martinelli, G, Altman, J, Roboz, G, Wang, ES, Burke, PW, Jeyakumar, D, Walter, RB, DeAngelo, DJ, Erba, HP, Advani, A, Gastaud, L, Thomas, X, Todisco, E, Pemmaraju, N, Mendez, L, de la Fuente, A, Gaidano, G, Curti, A, Boissel, N, Recher, C, Schliemann, C, Vyas, P, Sloss, CM, Wang, J, Malcolm, KA, Zweidler‐McKay, PA, Sweet, KL
Published 2022Conference item -
10
AML-262 Pivekimab Sunirine (PVEK, IMGN632) triplet with azacitidine and venetoclax shows broad activity in adverse genetic subsets of relapsed/refractory acute myeloid leukemia and... by Daver, N, Montesinos, P, Aribi, A, Martinelli, G, Altman, JK, Wang, ES, Roboz, GJ, Burke, PW, Gaidano, G, Walter, RB, Thomas, X, Jeyakumar, D, DeAngelo, DJ, Erba, HP, Todisco, E, Begna, K, Advani, A, Gastaud, L, de la Fuente, A, Curti, A, Mendez, LM, Vyas, P, Boissel, N, Vey, N, Recher, C, Longval, T, Platzbecker, U, Kapp-Schwörer, S, Schliemann, C, Konopleva, M, Torres, L, Sallman, DA, Marcucci, G, Marconi, G, Kantarjian, H, Sloss, CM, Malcolm, KE, Zweidler-McKay, PA, Sweet, K
Published 2022Journal article